Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leu

Cancer
Mahtab Jafari
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia
Myeloid and Monocytic Leukemia

Study Description

The purpose of this research is to explore the association between personality and adherence to oral cancer medication in patients with chronic myeloid leukemia (CML).

Eligibility

You can participate in this study if you are:

• 18 years of age or older

• Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP)

• Currently being treated with one of six cancer medications – imatinib, dasatinib, bosutinib, asciminib, ponatinib, or nilotinib

• A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or

• A member of a patient support group organized by the CML Buster Foundation

• Do not meet any of the criteria listed under “

Exclusion Requirements

You cannot participate in this study if

• Unable to read and speak English and Spanish

• Impaired decisional capacity to consent

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.